N-hydroxy-2-(naphthalen-2-yl)acetamide | 106359-52-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: N-hydroxy-2-(naphthalen-2-yl)acetamide
• 英文别名: N-hydroxy-2-naphthalen-2-ylacetamide
• CAS: 106359-52-8
• 化学式: C₁₂H₁₁NO₂
• mdl: MFCD09928145
• 分子量: 201.225
• InChiKey: IYXUERDUKOVYLR-UHFFFAOYSA-N

物化性质

• 密度：
  1.259±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.083
• 拓扑面积：
  49.3
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  N-hydroxy-2-(naphthalen-2-yl)acetamide 在 8-羟基喹啉 、 氟硼酸钠 、 carbonyl(pentamethylcyclopentadienyl)cobalt diiodide 、 silver carbonate 作用下， 以 二氯甲烷 为溶剂， 反应 3.0h， 生成 1,3-二氢-2H-苯并[g]吲哚-2-酮 、 1,3-dihydrobenzo[f]indol-2-one
  参考文献：
  名称：

  钴（III）催化的C（sp2）-H酰胺化反应在室温下苯并内酰胺的合成

  摘要：

  苯并融合的内酰胺，尤其是吲哚-2-酮和二氢喹啉-2-酮是在草和天然产品中流行的结构动机。在本文中，我们开发了室温并且通过钴（III）催化的C（sp 2）-H酰胺化反应稳定合成苯并融合的内酰胺。在该协议中，由Cp * Co（CO）I 2和配体原位形成Cp * Co（III）（配体）催化剂可简化钴配合物的合成工作。简单且易于合成的1,4,2-二恶唑5-1在室温下进行分子内CH酰胺化反应，并以高达86％的收率提供了多种功能化的苯并融合内酰胺。还证明了反应的可扩展性。

  DOI：

  10.1002/adsc.202001254
• 作为产物：
  描述：

  2-萘乙酸 在 N,N'-羰基二咪唑 、 盐酸羟胺 作用下， 以 四氢呋喃 为溶剂， 反应 1.0h， 生成 N-hydroxy-2-(naphthalen-2-yl)acetamide
  参考文献：
  名称：

  钴（III）催化的C（sp2）-H酰胺化反应在室温下苯并内酰胺的合成

  摘要：

  苯并融合的内酰胺，尤其是吲哚-2-酮和二氢喹啉-2-酮是在草和天然产品中流行的结构动机。在本文中，我们开发了室温并且通过钴（III）催化的C（sp 2）-H酰胺化反应稳定合成苯并融合的内酰胺。在该协议中，由Cp * Co（CO）I 2和配体原位形成Cp * Co（III）（配体）催化剂可简化钴配合物的合成工作。简单且易于合成的1,4,2-二恶唑5-1在室温下进行分子内CH酰胺化反应，并以高达86％的收率提供了多种功能化的苯并融合内酰胺。还证明了反应的可扩展性。

  DOI：

  10.1002/adsc.202001254

文献信息

• IDO inhibitors
  申请人：Mautino Mario

  公开号：US10047066B2

  公开（公告）日：2018-08-14

  Presently provided are methods for (a) modulating an activity of indoleamine 2,3-dioxygenase comprising contacting an indoleamine 2,3-dioxygenase with a modulation effective amount of a compound as described in one of the aspects described herein; (b) treating indoleamine 2,3-dioxygenase (IDO) mediated immunosuppression in a subject in need thereof, comprising administering an effective indoleamine 2,3-dioxygenase inhibiting amount of a compound as described in one of the aspects described herein; (c) treating a medical conditions that benefit from the inhibition of enzymatic activity of indoleamine-2,3-dioxygenase comprising administering an effective indoleamine 2,3-dioxygenase inhibiting amount of a compound as described in one of the aspects described herein; (d) enhancing the effectiveness of an anti-cancer treatment comprising administering an anti-cancer agent and a compound as described in one of the aspects described herein; (e) treating tumor-specific immunosuppression associated with cancer comprising administering an effective indoleamine 2,3-dioxygenase inhibiting amount of a compound as described in one of the aspects described herein; and (f) treating immunosuppression associated with an infectious disease, e.g., HIV-I infection, comprising administering an effective indoleamine 2,3-dioxygenase inhibiting amount a compound as described in one of the aspects described herein.

  目前提供的方法包括：(a) 调节吲哚胺2,3-二氧化酶的活性，包括将吲哚胺2,3-二氧化酶与本文描述的某一方面中描述的化合物的调节有效量接触；(b) 治疗需要吲哚胺2,3-二氧化酶（IDO）介导的免疫抑制的受试者，包括给予本文描述的某一方面中描述的化合物的有效吲哚胺2,3-二氧化酶抑制量；(c) 治疗受益于吲哚胺-2,3-二氧化酶酶活性抑制的医疗状况，包括给予本文描述的某一方面中描述的化合物的有效吲哚胺2,3-二氧化酶抑制量；(d) 增强抗癌治疗的有效性，包括给予抗癌药物和本文描述的某一方面中描述的化合物；(e) 治疗与癌症相关的肿瘤特异性免疫抑制，包括给予本文描述的某一方面中描述的化合物的有效吲哚胺2,3-二氧化酶抑制量；以及(f) 治疗与传染病相关的免疫抑制，例如HIV-I感染，包括给予本文描述的某一方面中描述的化合物的有效吲哚胺2,3-二氧化酶抑制量。
• IDO Inhibitors
  申请人：Mautino Mario

  公开号：US20110053941A1

  公开（公告）日：2011-03-03

  Presently provided are methods for (a) modulating an activity of indoleamine 2,3-dioxygenase comprising contacting an indoleamine 2,3-dioxygenase with a modulation effective amount of a compound as described in one of the aspects described herein; (b) treating indoleamine 2,3-dioxygenase (IDO) mediated immunosuppression in a subject in need thereof, comprising administering an effective indoleamine 2,3-dioxygenase inhibiting amount of a compound as described in one of the aspects described herein; (c) treating a medical conditions that benefit from the inhibition of enzymatic activity of indoleamine-2,3-dioxygenase comprising administering an effective indoleamine 2,3-dioxygenase inhibiting amount of a compound as described in one of the aspects described herein; (d) enhancing the effectiveness of an anti-cancer treatment comprising administering an anti-cancer agent and a compound as described in one of the aspects described herein; (e) treating tumor-specific immunosuppression associated with cancer comprising administering an effective indoleamine 2,3-dioxygenase inhibiting amount of a compound as described in one of the aspects described herein; and (f) treating immunosuppression associated with an infectious disease, e.g., HIV-I infection, comprising administering an effective indoleamine 2,3-dioxygenase inhibiting amount a compound as described in one of the aspects described herein.

  目前提供以下方法：(a) 通过接触本文中描述的化合物的调节有效量与吲哚胺2,3-二氧化酶相互作用，从而调节吲哚胺2,3-二氧化酶的活性；(b) 治疗需要吲哚胺2,3-二氧化酶(IDO)介导的免疫抑制的患者，包括给予本文中描述的化合物的有效吲哚胺2,3-二氧化酶抑制剂量；(c) 治疗需要抑制吲哚胺-2,3-二氧化酶酶活性的医疗状况，包括给予本文中描述的化合物的有效吲哚胺2,3-二氧化酶抑制剂量；(d) 增强抗癌治疗的有效性，包括给予抗癌剂和本文中描述的化合物；(e) 治疗与癌症相关的肿瘤特异性免疫抑制，包括给予本文中描述的化合物的有效吲哚胺2,3-二氧化酶抑制剂量；(f) 治疗与传染病相关的免疫抑制，例如HIV-1感染，包括给予本文中描述的化合物的有效吲哚胺2,3-二氧化酶抑制剂量。
• IDO INHIBITORS
  申请人：Newlink Genetics

  公开号：EP2227233A2

  公开（公告）日：2010-09-15
• [EN] IDO INHIBITORS<br/>[FR] INHIBITEURS DE L'IDO
  申请人：NEWLINK GENETICS

  公开号：WO2009073620A2

  公开（公告）日：2009-06-11

  Presently provided are methods for (a) modulating an activity of indoleamine 2,3-dioxygenase comprising contacting an indoleamine 2,3-dioxygenase with a modulation effective amount of a compound as described in one of the aspects described herein; (b) treating indoleamine 2,3-dioxygenase (IDO) mediated immunosuppression in a subject in need thereof, comprising administering an effective indoleamine 2,3-dioxygenase inhibiting amount of a compound as described in one of the aspects described herein; (c) treating a medical conditions that benefit from the inhibition of enzymatic activity of indoleamine-2,3-dioxygenase comprising administering an effective indoleamine 2,3-dioxygenase inhibiting amount of a compound as described in one of the aspects described herein; (d) enhancing the effectiveness of an anti-cancer treatment comprising administering an anti-cancer agent and a compound as described in one of the aspects described herein; (e) treating tumor-specific immunosuppression associated with cancer comprising administering an effective indoleamine 2,3-dioxygenase inhibiting amount of a compound as described in one of the aspects described herein; and (f) treating immunosuppression associated with an infectious disease, e.g., HIV-I infection, comprising administering an effective indoleamine 2,3-dioxygenase inhibiting amount a compound as described in one of the aspects described herein.
• Room Temperature Benzofused Lactam Synthesis Enabled by Cobalt(III)‐Catalyzed C( <i>sp</i> ² )−H Amidation
  作者：Xun Tian、Xin Li、Shengzu Duan、Ya Du、Tongqi Liu、Yongsheng Fang、Wen Chen、Hongbin Zhang、Minyan Li、Xiaodong Yang

  DOI：10.1002/adsc.202001254

  日期：2021.2.16

  Benzofused lactams, especially indolin‐2‐one and dihydroquinolin‐2‐one are popular structural motives in durgs and natural products. Herein, we developed a room temperature and robust synthesis of benzofused lactams through cobalt(III)‐catalyzed C(sp2)−H amidation. In this protocol, in‐situ formation of Cp*Co(III)(ligand) catalyst from Cp*Co(CO)I2 and ligand simplify the synthetic effort of cobalt

  苯并融合的内酰胺，尤其是吲哚-2-酮和二氢喹啉-2-酮是在草和天然产品中流行的结构动机。在本文中，我们开发了室温并且通过钴（III）催化的C（sp 2）-H酰胺化反应稳定合成苯并融合的内酰胺。在该协议中，由Cp * Co（CO）I 2和配体原位形成Cp * Co（III）（配体）催化剂可简化钴配合物的合成工作。简单且易于合成的1,4,2-二恶唑5-1在室温下进行分子内CH酰胺化反应，并以高达86％的收率提供了多种功能化的苯并融合内酰胺。还证明了反应的可扩展性。